Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials) The POWER 1 and 2 trials are phase 3, randomized, double-blind studies evaluating enobosarm, a selective androgen receptor modulator (SARM), for preventing and treating muscle wasting in patients undergoing first-line chemotherapy for non-small-cell lung cancer (NSCLC)
Sleep quality enhancement represents another significant value component, as improved rest supports cognitive function, immune health, and overall well-being
Benefits: Enhanced fat burning and lean mass gain Improved recovery and sleep Balanced energy levels 3X Blend (Tesamorelin + MGF + Ipamorelin) Purpose: Combines anabolic and restorative peptides for advanced performance and tissue repair
Together, these peptides allow researchers to examine parallel receptor activation, intracellular signaling convergence, and peptide interaction dynamics without prolonged circulation modification